Profile of patients with type 2 diabetes newly treated with GLP1 analogues in France and Spain

{"level_sex_clusion_I":[{"value":"Male","concept":{"vocab":"MeSH","vocabURI":"D008297"}},{"value":"Female","concept":{"vocab":"MeSH","vocabURI":"D005260"}}],"level_age_clusion_I":[{"value":"Young Adult (19 to 24 years)","concept":{"vocab":"MeSH","vocabURI":"D055815"}},{"value":"Adult (25 to 44 years)","concept":{"vocab":"MeSH","vocabURI":"D000328"}},{"value":"Middle Aged (45 to 64 years)","concept":{"vocab":"MeSH","vocabURI":"D008875"}},{"value":"Aged (65 to 79 years)","concept":{"vocab":"MeSH","vocabURI":"D000368"}},{"value":"Aged, 80 and over (80 years and more)","concept":{"vocab":"MeSH","vocabURI":"D000369"}}],"level_type_clusion_I":"Patients population","level_type_clusion_other":"","clusion_I":"adult ≥ 18 years, patient who accept to participate and who are able to read/understand the consent form and provide informed consent and who are not simultaneously participating in a study that included an investigational drug or procedure. Patients with a visit during the study period who recently initiated GLP1 analogue therapy (within 3 months prior to the visit) would be also enrolled in the survey if clinical data at initiation of the GLP1 treatment are available","clusion_E":""}